PRTA
Prothena Corporation plcNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$514.63M
P/E Ratio
—
EPS
$-2.81
Beta
-0.23
52W High
$11.80
52W Low
$4.32
50-Day MA
$10.03
200-Day MA
$9.57
Dividend Yield
—
Profit Margin
-260.90%
Forward P/E
10.63
PEG Ratio
0.80
About Prothena Corporation plc
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.
Fundamentals
| Revenue (TTM) | $57.94M |
| Gross Profit (TTM) | $-38.73M |
| EBITDA | $-92.33M |
| Operating Margin | 50.50% |
| Return on Equity | -40.30% |
| Return on Assets | -13.80% |
| Revenue/Share (TTM) | $1.08 |
| Book Value | $5.21 |
| Price-to-Book | 1.65 |
| Price-to-Sales (TTM) | 8.88 |
| EV/Revenue | 3.324 |
| EV/EBITDA | -3.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1706.00% |
| Shares Outstanding | $52.35M |
| Float | $36.75M |
| % Insiders | 20.05% |
| % Institutions | 90.57% |
Historical Volatility
HV 10-Day
71.21%
HV 20-Day
66.51%
HV 30-Day
57.05%
HV 60-Day
52.69%
HV Rank
86.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($21.40 target)
2
Strong Buy1
Buy2
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026